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There has been an intensive eﬀort to develop novel therapies for the treatment of metastatic colorectal cancer (mCRC). The
anti-epidermal growth factor receptor (EGFR) antibodies panitumumab and cetuximab and the anti-vascular endothelial growth
factor (VEGF) antibody bevacizumab have demonstrated clinical eﬃcacy and acceptable toxicity in the treatment of mCRC as
single agents or in combination with chemotherapy. Recent clinical trials have explored the eﬃcacy and safety of treatment
regimens incorporating chemotherapy in combination with bevacizumab and either panitumumab or cetuximab in patients
with mCRC. Results from the BOND-2 trial, which investigated cetuximab, bevacizumab, and chemotherapy in mCRC, provided
support for this therapeutic approach. Two large randomized phase 3 trials were initiated to evaluate ﬁrstline treatment of mCRC.
The Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) study investigated the eﬃcacy and safety of oxaliplatin-
or irinotecan-based chemotherapy and bevacizumab with or without panitumumab; CAIRO2 assessed the eﬃcacy and safety
of capecitabine/oxaliplatin and bevacizumab with or without cetuximab. In both trials, the combination of bevacizumab, an
EGFR-speciﬁc antibody, and chemotherapy in ﬁrst-line treatment of mCRC was associated with increased toxicity and no
improvement in patient outcome. These results suggest that these speciﬁc combinations should not be used in ﬁrst-line mCRC
outside investigational studies.
Copyright © 2009 John L. Marshall. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Colorectal cancer is among the most common cancers in
the United States, and it has been estimated that more
than 50000 patients died from colorectal cancer in 2007
[1]. Consequently, there is great interest in the devel-
opment of novel therapies for the disease. In particular,
recent studies have investigated the utility of treatment
with targeted therapies in combination with chemotherapy
in metastatic colorectal cancer (mCRC), with the aim of
improving antitumor activity while maintaining acceptable
toxicity. Moreover, there has been a belief that therapeutic
approaches using a combination of targeted therapies plus
c h e m o t h e r a p ym i g h tr e s u l ti ne v e ng r e a t e re ﬃcacy [2]. In
clinical studies, treatment with panitumumab, a fully human
immunoglobulin (Ig) G2 monoclonal antibody targeting the
epidermal growth factor receptor (EGFR), or cetuximab, a
chimeric IgG1 monoclonal antibody targeting the EGFR,
in combination with chemotherapy has been shown to
have antitumor activity and be well tolerated in mCRC
[3–7]. Additionally, panitumumab [8–10] and cetuximab
[5, 11]h a v ep r o v e nt ob ee ﬀective as single agents for
the treatment of mCRC in patients refractory to ﬁrst-line
treatment. Furthermore, treatment with bevacizumab, a
monoclonal antibody against vascular endothelial growth
factor (VEGF), in combination with chemotherapy results
in signiﬁcant improvements in survival and progression-free
survival compared with treatment with chemotherapy alone
[12–14].
Although combination therapies that include the anti-
EGFRantibodiespanitumumabandcetuximabhavedemon-
strated clinical eﬃcacy, some patients do not respond to
treatment [3–5]. At the time these trials were designed,
there were no known biomarkers that predicted response
to EGFR-targeted therapies in the treatment of mCRC.
AttemptstoassociateEGFRproteinexpressionwithresponse2 Journal of Oncology
to cetuximab were unsuccessful [5, 15]. However, activating
mutations in KRAS (a key component of the EGFR signaling
pathway [16]) have subsequently been associated with poor
outcomes in patients receiving cetuximab or panitumumab
[6, 17–26].
2.PreclinicalStudiesInvestigating
CombinedVascularEndothelialGrowth
Factor and Epidermal Growth Factor
Receptor Inhibition
Because VEGF and EGFR share downstream signaling com-
ponents, it has been suggested that there may be potential
for additive or even synergistic therapeutic eﬃcacy with
therapies targeting both pathways[27].In mice bearing GEO
colon cancer xenografts, simultaneous blockade of VEGF
and EGFR with a VEGF antisense oligonucleotide and cetux-
imab resulted in enhanced antitumor activity and improved
survival compared with inhibition of either pathway alone
[28]. Similarly, treatment with cetuximab in combination
with an anti-VEGF receptor 2 monoclonal antibody resulted
in improved antitumor activity in mice with metastases
induced by intraperitoneal injection of KM12L4 human
colon cancer cells [29]. In a preclinical model of gastric
cancer, inhibition of VEGF and EGFR signaling resulted
in signiﬁcantly improved inhibition of tumor growth [30].
Some evidence suggests that this improved inhibition in
preclinicalstudiesmayhavebeenduetointeractionsbetween
the VEGF and EGFR signaling pathways. For example,
treatment with an anti-EGFR monoclonal antibody was
shown to inhibit VEGF production; whereas treatment with
vandetanib (an inhibitor of the tyrosine kinase activity of
VEGF receptors) blocked epidermal growth factor-induced
EGFR phosphorylation [31, 32].
3. Phase II Combination Studies of
VascularEndothelialGrowthFactor
Inhibitorsand EpidermalGrowth
Factor Receptor Inhibitors
Encouraging results have been obtained in phase II studies
that investigated regimens incorporating chemotherapy in
combination with bevacizumab and an EGFR inhibitor in
the treatment of mCRC. BOND-2 was a small (N = 83),
randomized, phase II trial that evaluated the safety and
eﬃcacy of cetuximab and bevacizumab with or without
irinotecaninpatientswithirinotecan-refractorymCRC[33].
The patient population enrolled in the trial had received
extensive previous treatment; the median number of prior
chemotherapy regimens was 3. Patients in arm A (n = 43) of
the study received cetuximab, bevacizumab, and irinotecan;
whereas patients in arm B (n = 40) received only cetuximab
plus bevacizumab. Treatment continued until disease pro-
gression per Response Evaluation Criteria in Solid Tumors
(RECIST) criteria, unacceptable toxicity, or the patient with-
drew consent. Patients receiving cetuximab, bevacizumab,
and irinotecan had a time to tumor progression of 7.3
months, a response rate of 37%, and an overall survival of
14.5 months. In comparison, patients receiving cetuximab
and bevacizumab without irinotecan had a time to tumor
progression of 4.9 months, a response rate of 20%, and
an overall survival of 11.4 months. These response rates
compare favorably with those from other studies in patients
with refractory mCRC. In the BOND-1 study, patients
with irinotecan-refractory mCRC treated with cetuximab
with (n = 218) or without (n = 111) irinotecan had
response rates of 23% and 11%, respectively [5]. In the EPIC
study, patients with mCRC refractory to ﬂuoropyrimidine
and oxaliplatin treatment received irinotecan with (n =
648) or without (n = 650) cetuximab and had response
rates of 16% and 4%, respectively [4]. In a study of
bevacizumab in combination with oxaliplatin, patients with
mCRC refractory to ﬂuoropyrimidine and irinotecan were
treatedwithFOLFOXplusbevacizumab(n = 286),FOLFOX
alone (n = 291), or bevacizumab alone (n = 243). Overall
response rates in these treatment groups were 23%, 9%, and
3%,respectively[12].Finally,patientstreatedwithirinotecan
(CPT-11) as a second-line therapy had overall response rates
ranging from 13% to 25% [34, 35].
In addition to the encouraging activity observed in
BOND-2, the incidence of toxicity attributable to cetuximab,
which consisted chieﬂy of skin rash, was similar with
and without irinotecan, suggesting that the addition of
irinotecan to the cetuximab/bevacizumab combination did
not exacerbate toxicity. However, because of the trial design,
no comparison of the toxicity or antitumor activity of this
combination with the combination of bevacizumab and
irinotecan could be made.
Inanothersmall(N = 35)phaseIItrial,Meyerhardtetal.
investigated the eﬃcacy and safety of a combination of FOL-
FOX chemotherapy, bevacizumab (5mg/kg intravenously),
and erlotinib (150mg/d orally) in the ﬁrst-line treatment
of patients with mCRC [36]. This combination resulted
in an overall response rate of 34% (95% CI, 18%–50%).
In addition to this relatively low response rate (response
rates of greater than 47% have been reported in patients
receiving bevacizumab plus chemotherapy as a ﬁrst-line
treatment for mCRC [37, 38]), 86% of patients experienced
grade 3/4 adverse events. Many withdrew owing to toxicity
(51%) or withdrew consent owing to toxic eﬀects (26%),
limiting conclusions regarding eﬃcacy. It is unclear whether
the use of a small-molecule inhibitor of the EGFR (i.e.,
erlotinib) may have resulted in diﬀerences in antitumor
activity and tolerability of this combination compared with
use of an anti-EGFR monoclonal antibody in combination
with bevacizumab.
Collectively, data from preclinical and phase II clinical
studiessuggestedthatcombinationtherapiestargetingVEGF
and EGFR in combination with chemotherapy might result
in improved antitumor eﬃcacy in patients with mCRC but
retain acceptable toxicity. However, some results suggest
that outcomes using this approach may be diﬀerent in
patients receiving this combination as ﬁrst-line therapy and
highly selected second-line therapy or late-stage patient
populations.
Results from several other studies have suggested that
inhibition of the VEGF and EGFR pathways may haveJournal of Oncology 3
activity in other tumor types. Combining bevacizumab
and an EGFR inhibitor appears to show antitumor activity
and acceptable toxicity in the second-line treatment of
advanced nonsmall cell lung cancer (NSCLC) [27, 39]a n d
recurrent or metastatic squamous cell carcinoma of the head
and neck [40]. Furthermore, treatment with chemotherapy,
bevacizumab, and an EGFR inhibitor appears to be a
promising treatment approach in patients with advanced
NSCLC [41].
4. Safety andEfﬁcacy of Regimens
Incorporating Chemotherapy, Vascular
Endothelial GrowthFactorInhibitors,
and Epidermal Growth Factor Receptor
InhibitorsinPatients withMetastatic
Colorectal Cancer
To date, 2 large phase 3 trials investigating the safety and
eﬃcacy of combination therapies incorporating chemother-
apy, bevacizumab, and an EGFR inhibitor for ﬁrst-line treat-
ment of mCRC have recently been completed [42]. These
trials were designed based on results from the hypothesis-
generating BOND-2 trial, and both were designed and
accrued before the identiﬁcation of KRAS mutations as
a predictor of poor response to anti-EGFR monoclonal
antibodies. In both studies, the combination of chemother-
apy, bevacizumab, and an EGFR inhibitor was associated
with decreased eﬃcacy. Furthermore, both regimens were
associated with substantial toxicity.
Panitumumab Advanced Colorectal Cancer Evaluation
(PACCE) was a randomized, open-label, phase 3 trial to
evaluate patients undergoing ﬁrst-line treatment for mCRC
with either oxaliplatin- or irinotecan-based chemotherapy
and bevacizumab, with or without panitumumab [43].
At the time the study was designed, both FOLFOX and
FOLFIRI had been shown to be superior to infusional
5-ﬂuorouracil/leucovorin [44, 45], and the 2 regimens
appeared to be interchangeable in mCRC [46]. Furthermore,
results of the ECOG3200 study had demonstrated improved
survivalwiththecombinationofbevacizumabplusFOLFOX
compared with FOLFOX alone as a second-line therapy in
mCRC[12].Basedonthesedata,oxaliplatin-andirinotecan-
based chemotherapy regimens were selected for use in
PACCE,withthepreponderanceofpatients(∼80%)enrolled
in the oxaliplatin-based chemotherapy arm because more
substantial data were available supporting the combination
of bevacizumab plus oxaliplatin-based chemotherapy and
because it was intended that the trial should match the stan-
dard of care for ﬁrst-line treatment of mCRC in community
practice. Patients received no panitumumab (n = 410) or
6mg/kg panitumumab (n = 413) every 2 weeks in the
oxaliplatin/bevacizumab arm and no panitumumab (n =
115) or 6mg/kg panitumumab (n = 115) every 2 weeks
in the irinotecan/bevacizumab arm. Treatment continued
until disease progression or drug intolerability. There was
a signiﬁcant diﬀerence in progression-free survival (10.0
versus 11.4 months; hazard ratio [HR], 1.27; 95% CI, 1.06–
1.52) and overall survival (19.4 versus 24.5 months; HR,
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Figure 1: Median overall survival in PACCE and CAIRO2. Bev:
bevacizumab; Cap: capecitabine; Cmab: cetuximab; Iri: irinotecan;
Ox: oxaliplatin; Pmab: panitumumab.
1.43; 95% CI, 1.11–1.83) in favor of the control group in
the oxaliplatin arm (Table 1; Figure 1). In the irinotecan
arm, progression-free survival was 10.1 months for the
panitumumab group and 11.7 months for the control group
(HR, 1.19; 95% CI, 0.79–1.79). Median overall survival in
the irinotecan arm was 20.7 months for the panitumumab
group and 20.5 months for the control group (HR, 1.42;
95% CI, 0.79–2.62). The response rates were similar between
the panitumumab and control groups in both the oxaliplatin
arm (46% and 48%, resp.; odds ratio [OR], 0.92; 95% CI,
0.70–1.22) and the irinotecan arm (43% and 40%; OR, 1.11;
95% CI, 0.65–1.90). Grade 3/4 adverse events were increased
in both chemotherapy cohorts among patients who received
panitumumab. Adverse events occurring more frequently in
patients receiving panitumumab compared with the control
arm included skin toxicity, diarrhea, dehydration, hypo-
magnesemia,infections,andpulmonaryembolism(Table 2).
Treatment with panitumumab in PACCE was terminated
earlyasaresultofanobservedlackofadditional clinicalben-
eﬁt and increased toxicity at a preplanned interim analysis.
CAIRO2 was a randomized, open-label, phase 3 trial
that evaluated the eﬃcacy and safety of bevacizumab and
capecitabine/oxaliplatinwithorwithoutcetuximabasaﬁrst-
line treatment in 755 patients with mCRC [47]. Patients
received capecitabine and oxaliplatin in combination with
either bevacizumab (n = 368) or bevacizumab and cetux-
imab (n = 368). To prevent potential neurotoxicity, patients
received a maximum of 6 cycles of oxaliplatin. Although
it is unclear how many patients received oxaliplatin at a
later time, 48 patients received oxaliplatin following disease
progression, including 18 in the control group and 30 in
thecetuximabgroup.Patientsreceivingchemotherapy,beva-
cizumab, and cetuximab had a decreased progression-free
survival time, the primary endpoint of the study, compared
with patients receiving chemotherapy and bevacizumab (9.4
versus 10.7 months, resp.; HR, 1.22; 95% CI, 1.04–1.43;
see Table 1). The response rate and median overall survival
were not signiﬁcantly diﬀerent between the cetuximab and
control groups (52.7% versus 50.0% and 19.4 versus 20.34 Journal of Oncology
Table 1: Comparison of eﬃcacy results from the PACCE and CAIRO2 studies.
PACCE oxaliplatin cohort [43]C A I R O 2 [ 47]
(N = 823) (N = 755)
O x+B e v+P m a b O x+B e v C a p ,O x+B e v+C m a b C a p ,O x+B e v
Median progression-free survival (95% CI), mo 10.0 (8.9–11.0) 11.4 (10.5–11.9) 9.4 (8.4–10.5) 10.7 (9.7–12.3)
Progression-free survival events, n (%) 246 (60) 221 (54) 316 (84) 293 (78)
Overall response rate, %∗ 46 48 50.0 52.7
Median overall survival (95% CI), mo 19.4 (18.4–20.8) 24.5 (20.4–24.5) 20.3 (17.8–24.7) 19.4 (17.5–21.4)
Deaths, n (%) 143 (35) 108 (26) 214 (57) 193 (51)
Bev: bevacizumab; Cap: capecitabine; Cmab: cetuximab; NR: not reported; Ox: oxaliplatin; PACCE: Panitumumab Advanced Colorectal Cancer Evaluation;
Pmab: panitumumab.
∗Overall response rate = complete response + partial response.
Table 2: Comparison of adverse events of interest in the PACCE and CAIRO2 studies.
PACCE oxaliplatin cohort [43]C A I R O 2 [ 47]
(N = 823) (N = 755)
O x+B e v+P m a b O x+B e v C a p ,O x+B e v+C m a b C a p ,O x+B e v
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3/4 Grade 3/4
Incidence of toxicity, %
Skin toxicity 35 1 1 0 39.1 20.8
Diarrhea 22 2 12 1 26.0 19.1
Infection 16 2 8 2 6.0 6.8
H y p e r t e n s i o n 405 0 9 . 3 1 4 . 8
H y p o m a g n e s e m i a 310 0 N R N R
Neuropathy∗ 3 <1 7 0 7.7 10.4
Nausea/vomiting† 13 0 6 1 6.3/6.0∗ 8.5/8.2∗
Deep vein thrombosis 7 0 8 0 NR NR
Pulmonary embolism 0 6 0 4 NR NR
Venous thromboembolic events NR NR NR NR 8.2 6.8
Arterial thromboembolic events NR NR NR NR 2.2 3.3
Bev: bevacizumab; Cap: capecitabine; Cmab: cetuximab; NR: not reported; Ox: oxaliplatin; PACCE: Panitumumab Advanced Colorectal Cancer Evaluation;
Pmab: panitumumab.
∗Neuropathy events were reported as “sensory neuropathy” in CAIRO2.
†The incidence of nausea and vomiting was reported together in PACCE but as separate adverse events in CAIRO2. The ﬁrst number indicates the reported
incidence of nausea and the second number indicates the incidence of vomiting.
months, resp.; see Figure 1). The overall incidence of grade
3/4 toxicity was signiﬁcantly increased in patients treated
with chemotherapy, bevacizumab, and cetuximab compared
with patients receiving chemotherapy and bevacizumab. The
most frequent grade 3/4 toxicities were diarrhea, acneiform
rash, hand-foot skin reaction, fatigue, hypertension, and
sensory neuropathy (Table 2).
5. Biomarkers for the Prediction of
Response in Regimens Incorporating
Chemotherapy, VascularEndothelial
GrowthFactor Inhibitors,and Epidermal
Growth Factor Receptor Inhibitors
There has been growing interest in the development of
biomarkers for the identiﬁcation of patients most likely to
respond to therapy. At the time PACCE and CAIRO2 were
initiated, mutations of codons 12 and 13 of the KRAS gene
had been associated with poor prognosis in mCRC [48–50].
Furthermore, KRAS mutations were subsequently found to
be associated with poor response to either panitumumab or
cetuximab either alone or in combination with chemother-
apy [6, 17–26]. For example, in a study of panitumumab
plus best supportive care compared with best supportive care
alone in second-line treatment of mCRC, clinical beneﬁt was
conﬁnedto patients withwild-type KRAS[17].The response
rate among patients with wild-type KRAS was 17%, whereas
no patient with mutant KRAS had a response.
In PACCE, KRAS mutations (codons 12 or 13) were
identiﬁed in 346 of 865 (40%) samples evaluated (39% in the
oxaliplatin cohort and 43% in the irinotecan cohort) [43].
Progression-free survival was longer among patients who
did not receive panitumumab in both chemotherapy cohorts
among patients with both wild-type and mutant KRAS
(Table 3). In the oxaliplatin-based chemotherapy cohort,
response rates were similar between arms in both KRAS
subsets (Table 3). Surprisingly, overall survival favored theJournal of Oncology 5
Table 3: Association between KRAS status and eﬃcacy in PACCE and CAIRO2.
Response rate, % Progression-free survival, mo Overall survival, mo
Wild-type Mutant Wild-type Mutant Wild-type Mutant
KRAS KRAS KRAS KRAS KRAS KRAS
PACCE oxaliplatin cohort [43]( N = 664)
Ox + Bev + Pmab 50 47 9.8 10.4 20.7 19.3
Ox + Bev 56 44 11.5 11.0 24.5 19.3
CAIRO2 [47]( N = 528)
Cap, Ox + Bev + Cmab 61.4 45.9 10.5 8.1 21.8 17.2
Cap, Ox + Bev 50.0 59.2 10.6 12.5 22.4 24.9
Bev: bevacizumab; Cap: capecitabine; Cmab: cetuximab; NR: not reported; Ox: oxaliplatin; PACCE: Panitumumab Advanced Colorectal Cancer Evaluation;
Pmab: panitumumab.
controlgroupinthewild-typesubsetoftheoxaliplatin-based
chemotherapy cohort (24.5 versus 20.7 months; HR, 1.89;
95% CI, 1.30–2.75). In the irinotecan-based chemother-
apy cohort, response rates were higher in the wild-type
KRAS subset among patients who received panitumumab
compared with those in the control group (54% versus
48%). In the mutant KRAS subset, response rates were
lower among patients who received panitumumab (30%
v e r s u s3 8 % ) .O v e r a l ls u r v i v a lf a v o r e dt h ec o n t r o la r ma n d
was not inﬂuenced by KRAS status in the irinotecan-based
chemotherapy cohort.
In CAIRO2, KRAS mutations were identiﬁed in 206 of
528 (39.6%) patients [47]. Forty-one percent of patients
in the control arm and 38% of patients in the cetuximab
arm had mutations in KRAS. Progression-free survival was
similar between the cetuximab and control arms in the
wild-type KRAS subset but favored the control arm in the
mutant KRAS subset (12.5 versus 8.1 months). There was
no association between KRAS s t a t u sa n do v e r a l ls u r v i v a li n
either arm (Table 3). Thus, unlike previous studies, which
have demonstrated that KRAS mutations predict a poor
response to EGFR inhibitors, KRAS mutational status in
PACCE and CAIRO2 failed to predict patient response to
an anti-EGFR antibody when administered in combination
with bevacizumab and chemotherapy.
Associations between response in BOND-2 and germline
polymorphisms in a variety of genes have been investigated.
It was found that polymorphisms in EGF, the gene that
encodes EGF, were associated with tumor response in
patients who received cetuximab, bevacizumab, and irinote-
can [51]. EGF polymorphisms aﬀect EGF expression [52]
and have been associated with improved survival in mCRC
patients treated with cetuximab and irinotecan [53].
6. Discussion
Collectively, the results of these trials suggest that the use of
combination therapies consisting of bevacizumab, an EGFR-
speciﬁc antibody, and chemotherapy in the ﬁrst-line treat-
ment of mCRC is associated with negative risk beneﬁt. This
combination was not associated with improved outcomes in
patients receiving panitumumab and in patients receiving
cetuximab, suggesting aclasseﬀectof EGFR inhibitors rather
than a speciﬁc eﬀect of either of the agents. Although there
may be diﬀerences in the safety proﬁles of panitumumab
and cetuximab, the similarity of the results of PACCE and
CAIRO2suggeststhat,inthecontextofcombinationtherapy
with bevacizumab and chemotherapy, their similarities out-
weigh their diﬀerences. These results were surprising given
theresultsoftheBOND-2studyinwhichthecombinationof
cetuximab and bevacizumab with irinotecan appeared to be
eﬀective in patients with irinotecan-refractory mCRC. The
diﬀerence in the results of BOND-2 and PACCE/CAIRO2
studies may reﬂect diﬀerences in patient selection among the
3 trials.
Overall, the results of PACCE and CAIRO2 were similar.
In both studies, the combination of an EGFR-speciﬁc mono-
clonal antibody, bevacizumab, and chemotherapy resulted in
signiﬁcantly reduced progression-free survival and exacerba-
tion of toxicity compared with treatment with bevacizumab
andchemotherapy.Intheoxaliplatin armofPACCE (butnot
the irinotecan arm), a signiﬁcant decrease in overall survival
was observed. This decrease in survival might have been due
toreducedchemotherapydoseintensityinthepanitumumab
arms. Although no decrease in overall survival was observed
in patients who received cetuximab in CAIRO2, this was not
the primary endpoint of the study, and it is unclear whether
the study was powered to detect a change in overall survival
inthe2arms.Itisalsointerestingtonotethatoverallsurvival
in the bevacizumab/oxaliplatin arm (24.5 months) was rela-
tively long compared with survival in other phase III studies
that have investigated bevacizumab in combination with
oxaliplatin-based chemotherapy, including the NO16966
trial (21.3 months) [38] and CAIRO2 (20.3 months) [47].
The results of PACCE and CAIRO2 are interesting given that
treatment with panitumumab, cetuximab, or bevacizumab
in combination with chemotherapy has antitumor activity
and acceptable toxicity in mCRC [3–6, 12–14]. There are
several potential explanations for the exacerbated toxicities.
First, there may have been a pharmacodynamic interaction
between the agents. For example, treatment with an EGFR-
speciﬁc antibody may have altered downstream signaling
required for bevacizumab or chemotherapy activity, or
alternatively,bevacizumabmayhavealteredsignalingactivity
required for anti-EGFR monoclonal antibody activity. Sec-
ond, there may have been trial design factors that inﬂuenced
toxicity. Potentially, toxicity reporting bias due to the open-
labeldesignmayhavecontributedtothediﬀerenceinadverse6 Journal of Oncology
events in the treatment arms. Alternatively, treatment dis-
continuation in patients without disease progression may
have reduced the ability to observe some treatment eﬀects.
Finally, there may have been pharmacokinetic interactions
between the agents.
Although these results suggest that VEGF/EGFR/chemo-
therapy combination regimens are problematic in mCRC,
the lack of beneﬁt associated with each regimen in ﬁrst-line
therapy should not be generalized to each of the individual
agents or to any of the chemotherapy-plus-monoclonal
antibody combinations. In particular, the exacerbation of
toxicity observed should not be ascribed to either cetuximab
or panitumumab merely because these were the agents
added to the bevacizumab plus chemotherapy combination,
and the trial designs did not include panitumumab plus
chemotherapy or cetuximab plus chemotherapy arms. To
date, panitumumab combined with chemotherapy regimens
has been well tolerated. Recent results from 2 large phase
3 trials for ﬁrst- and second-line mCRC have shown
that panitumumab has acceptable toxicity in combination
with chemotherapy. In phase 2 studies, treatment with
panitumumab with chemotherapy has shown encouraging
antitumor activity [3, 54]. Cetuximab is approved for use
in combination with irinotecan for second-line treatment of
mCRC [55].
Because of the encouraging results in BOND-2, PACCE
and CAIRO2 were conducted before additional data were
gathered from phase 1, 2, or randomized phase 2 studies.
Notably, BOND-2 was composed of a treatment arm
consisting of only biologics without chemotherapy and a
treatment arm consisting of biologics and irinotecan only.
At present, the contribution of diﬀerent chemotherapy
regimens in PACCE (leucovorin/5-ﬂuorouracil/irinotecan,
or leucovorin/5-ﬂuorouracil/oxaliplatin) or CAIRO2 (cape-
citabine/oxaliplatin) contributed to the observed toxicity.
Moreover, it is unknown whether alternative chemotherapy
combinations may have resulted in better outcomes.
Reasons for variability in observed associations between
KRAS status and response and overall survival in PACCE
and CAIRO2 remain unclear [43, 47]. Even among patients
with wild-type KRAS, the negative interaction between
bevacizumab and panitumumab appeared to counteract this
potential advantage. However, it should be noted that, in
PACCE, KRAS data were from an unplanned retrospective
subsetanalysisandarenotdeﬁnitive.Somecomparisonsmay
represent chance ﬁndings resulting from the small sample
size. Diﬀerential exposure to EGFR inhibitors in later lines
of therapy for the control arm of PACCE might have aﬀected
survival outcomes in the KRAS wild-type group. Biomarkers
in addition to KRAS may have also inﬂuenced outcome.
BRAF mutations (V600E) [18,56],PTEN gene ampliﬁcation
[57], and EGFR ligand expression levels [19]h a v eb e e n
identiﬁed as potential predictive markers for EGFR-targeted
therapies in mCRC [18, 19]. A recently published retrospec-
tive analysis of tumor samples from CAIRO2 demonstrated
that BRAF mutations were associated with poor clinical
outcome [58]. Of the 516 tumors available for analysis, 45
(8.7%) tumors had BRAF V600E mutations. Consistent with
previous studies [56, 59], BRAF mutations were observed
only in tumors with wild-type KRAS. Across both treatment
arms in the study, the presence of BRAF mutations was
associated with signiﬁcant reductions in median overall
survival and progression-free survival compared with wild-
type BRAF but the response rate was unaﬀected [58].
However, the presence or BRAF mutations did not appear
to be associated with poor response to cetuximab, suggesting
that BRAF may be a better predictor of prognosis than
of response to VEGF/EGFR inhibition. The contribution
of potential biomarkers such as BRAF mutations to the
outcomeofpatientsisunknown.Furthermore,itisunknown
whether there were imbalances in these markers across the
treatment arms in PACCE. Results of pharmacogenomic
analyses of BOND-2 suggest that biomarkers that predict
response in this combination might be found [51]; however,
at present this hypothesis remains untested.
The results of PACCE and CAIRO2 are likely to aﬀect
the conduct and design of current and future studies. In
particular, the open-label, phase III CALGB 80405 study
was designed to determine if cetuximab with or without
bevacizumab in combination with chemotherapy (FOLFOX
or FOLFIRI) improves overall survival in the ﬁrst-line
treatment of patients with mCRC [60]. Enrollment in arm
C (chemotherapy with bevacizumab and cetuximab) was
suspended by the sponsor. Concerns raised by PACCE
and CAIRO2 have also resulted in the suspension of the
randomizedphaseIIISWOG0600study,whichwasdesigned
toinvestigateirinotecan-basedchemotherapyandcetuximab
with or without bevacizumab for the treatment of patients
with mCRC refractory to bevacizumab in combination
with chemotherapy. Interestingly, preliminary results of the
BOND 2.5 study, which assessed cetuximab and beva-
cizumab in combination with irinotecan-based chemother-
apy in patients with mCRC refractory to bevacizumab in
combinationwithirinotecan-basedchemotherapy,suggested
that although the combination had acceptable toxicity,
response rates among these patients appeared inferior to
that observed in BOND-2 [61]. The objective response rate
was 9% and median time to progression was 3.9 months.
These results suggest that patient selection may be of critical
importance in the design of trials investigating combinations
of chemotherapy and EGFR inhibitors with bevacizumab.
7. Conclusions
The results of PACCE, CAIRO2, and other trials do not
support the use of therapies consisting of chemotherapy in
combination with a VEGF inhibitor and an EGFR inhibitor
as a ﬁrst-line therapy for mCRC outside investigational
studies. Although it is possible that additional investigational
studies may identify combinations that provide clinical
beneﬁt in either the ﬁrst- or second-line settings, it will be
necessary to carefully design and monitor these studies given
the exacerbated toxicity observed in PACCE and CAIRO2.
Careful patient selection is likely to be a key determinant
of any future success of VEGF/EGFR regimens. Despite
the results of PACCE and CAIRO2, it must be noted that
combination therapy with chemotherapy and bevacizumabJournal of Oncology 7
or chemotherapy and panitumumab or cetuximab is still
associated with therapeutic beneﬁt in mCRC.
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